Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2853) 2853
Newsletter (14) 14
Book Chapter (9) 9
Newspaper Article (4) 4
Magazine Article (3) 3
Dissertation (2) 2
Publication (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2492) 2492
mitoxantrone - administration & dosage (1965) 1965
science & technology (1876) 1876
life sciences & biomedicine (1815) 1815
female (1699) 1699
middle aged (1502) 1502
male (1478) 1478
antineoplastic combined chemotherapy protocols - therapeutic use (1399) 1399
adult (1276) 1276
biological and medical sciences (1156) 1156
medical sciences (1148) 1148
aged (1106) 1106
oncology (1012) 1012
mitoxantrone (934) 934
chemotherapy (848) 848
pharmacology. drug treatments (806) 806
antineoplastic agents (753) 753
cytarabine - administration & dosage (640) 640
antineoplastic combined chemotherapy protocols - adverse effects (594) 594
treatment outcome (590) 590
mitoxantrone - adverse effects (569) 569
hematology (518) 518
remission induction (478) 478
mitoxantrone - therapeutic use (453) 453
etoposide - administration & dosage (426) 426
cyclophosphamide - administration & dosage (407) 407
antineoplastic combined chemotherapy protocols - administration & dosage (398) 398
adolescent (376) 376
breast neoplasms - drug therapy (367) 367
animals (357) 357
drug administration schedule (357) 357
antineoplastic agents - administration & dosage (328) 328
leukemia, myeloid, acute - drug therapy (303) 303
cancer (298) 298
combined modality therapy (294) 294
disease-free survival (280) 280
vincristine - administration & dosage (278) 278
survival analysis (276) 276
survival rate (267) 267
aged, 80 and over (265) 265
pharmacology & pharmacy (263) 263
prednisone - administration & dosage (258) 258
doxorubicin - administration & dosage (254) 254
prognosis (254) 254
antineoplastic agents - therapeutic use (250) 250
dose-response relationship, drug (227) 227
tumors (227) 227
follow-up studies (208) 208
recurrence (204) 204
abridged index medicus (203) 203
mitoxantrone hydrochloride (200) 200
lymphoma, non-hodgkin - drug therapy (199) 199
daunorubicin - administration & dosage (194) 194
multiple sclerosis (191) 191
hematologic and hematopoietic diseases (190) 190
acute disease (186) 186
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (180) 180
time factors (179) 179
methotrexate - administration & dosage (176) 176
mice (175) 175
mitoxantrone - pharmacology (175) 175
prostatic neoplasms - drug therapy (174) 174
breast neoplasms - pathology (171) 171
drug evaluation (167) 167
retrospective studies (165) 165
breast cancer (164) 164
fluorouracil - administration & dosage (161) 161
drug therapy (156) 156
prospective studies (156) 156
care and treatment (155) 155
mitoxantrone - pharmacokinetics (155) 155
neurosciences & neurology (155) 155
medicine & public health (144) 144
research (144) 144
vidarabine - analogs & derivatives (143) 143
leukemia, myeloid - drug therapy (142) 142
prednisolone - administration & dosage (141) 141
clinical neurology (138) 138
neoplasm staging (137) 137
vidarabine - administration & dosage (137) 137
salvage therapy (134) 134
multiple sclerosis - drug therapy (131) 131
prostate cancer (131) 131
antineoplastic agents - adverse effects (130) 130
drug resistance, neoplasm (130) 130
cisplatin - administration & dosage (129) 129
child (126) 126
cell line, tumor (124) 124
antineoplastic agents - pharmacology (122) 122
neoplasm metastasis (121) 121
cytarabine - adverse effects (118) 118
clinical trials as topic (109) 109
neurology (109) 109
rituximab (108) 108
hematopoietic stem cell transplantation (107) 107
health aspects (106) 106
acute myeloid leukemia (105) 105
disease progression (103) 103
leukemia (101) 101
drug resistance (100) 100
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2682) 2682
Japanese (105) 105
German (64) 64
Chinese (45) 45
French (29) 29
Spanish (18) 18
Russian (15) 15
Czech (6) 6
Hungarian (4) 4
Italian (4) 4
Polish (3) 3
Ukrainian (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
by Chiappella, Annalisa and Martelli, Maurizio and Angelucci, Emanuele and Brusamolino, Ercole and Evangelista, Andrea and Carella, Angelo Michele and Stelitano, Caterina and Rossi, Giuseppe and Balzarotti, Monica and Merli, Francesco and Gaidano, Gianluca and Pavone, Vincenzo and Rigacci, Luigi and Zaja, Francesco and D'Arco, Alfonso and Cascavilla, Nicola and Russo, Eleonora and Castellino, Alessia and Gotti, Manuel and Congiu, Angela Giovanna and Cabras, Maria Giuseppina and Tucci, Alessandra and Agostinelli, Claudio and Ciccone, Giovannino and Pileri, Stefano A and Vitolo, Umberto
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
by Rieger, M and Österborg, A and Pettengell, R and White, D and Gill, D and Walewski, J and Kuhnt, E and Loeffler, M and Pfreundschuh, M and Ho, A.D and for the MabThera International Trial (MInT) Group and MabThera Int Trial Grp and MabThera International Trial (MInT) Group
Annals of oncology, ISSN 0923-7534, 03/2011, Volume 22, Issue 3, pp. 664 - 670
primary mediastinal B-cell lymphoma | MInT | rituximab | Rituximab | Primary mediastinal B-cell lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Leucovorin - administration & dosage | Multivariate Analysis | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, B-Cell - radiotherapy | Male | Young Adult | Mediastinal Neoplasms - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Mediastinal Neoplasms - radiotherapy | Adolescent | Methotrexate - administration & dosage | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
by Parker, Catriona, PhD and Waters, Rachel, MSc and Leighton, Carly, BNurs and Hancock, Jeremy, PhD and Sutton, Rosemary, PhD and Moorman, Anthony V, PhD and Ancliff, Philip, FRCPath and Morgan, Mary, MRCPath and Masurekar, Ashish, MD and Goulden, Nicholas, FRCPath and Green, Nina and Révész, Tamas, FRACP and Darbyshire, Philip, FRCPath and Love, Sharon, BSc and Saha, Vaskar, Prof
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Databases | Cytogenetics | Cancer therapies | Cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
by Cortes, Jorge E and Goldberg, Stuart L and Feldman, Eric J and Rizzeri, David A and Hogge, Donna E and Larson, Melissa and Pigneux, Arnaud and Recher, Christian and Schiller, Gary and Warzocha, Krzysztof and Kantarjian, Hagop and Louie, Arthur C and Kolitz, Jonathan E
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
Phase II | Chemotherapy Intervention | Acute Myeloid Leukemia | First Relapse | Acute myeloid leukemia | First relapse | Chemotherapy intervention | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Mitoxantrone - administration & dosage | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Aminoglycosides - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Daunorubicin - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Amsacrine - administration & dosage | Vidarabine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Cladribine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Injections | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Vidarabine - administration & dosage | Liposomes | Salvage Therapy - methods | Chemotherapy | Usage | Health aspects | Patient outcomes | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Sequential therapy with alternating short courses of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R‐FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma
by Derenzini, Enrico and Casadei, Beatrice and Broccoli, Alessandro and Gandolfi, Letizia and Pellegrini, Cinzia and Zinzani, Pier Luigi
British journal of haematology, ISSN 0007-1048, 08/2014, Volume 166, Issue 4, pp. 625 - 628
sequential therapy | follicular lymphoma | autologous stem cell transplantation | Sequential therapy | Follicular lymphoma | Autologous stem cell transplantation | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Lymphoma, Follicular - therapy | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Treatment Outcome | Stem Cell Transplantation - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epothilones - administration & dosage | Vincristine - administration & dosage | Adult | Female | Aged | Combined Modality Therapy - methods | Doxorubicin - administration & dosage | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Stem cells | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
by de Bono, Johann Sebastian, Dr and Oudard, Stephane, MD and Ozguroglu, Mustafa, MD and Hansen, Steinbjørn, MD and Machiels, Jean-Pascal, MD and Kocak, Ivo, MD and Gravis, Gwenaëlle, MD and Bodrogi, Istvan, MD and Mackenzie, Mary J, MD and Shen, Liji, PhD and Roessner, Martin, MS and Gupta, Sunil, MD and Sartor, A Oliver, MD and for the TROPIC Investigators and TROPIC Investigators
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1147 - 1154
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the urinary system | Urinary tract. Prostate gland | Gynecology. Andrology. Obstetrics | General aspects | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Male genital diseases | Tumors | Prostatic Neoplasms - metabolism | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms - immunology | Antineoplastic Agents, Hormonal - therapeutic use | Treatment Failure | Neutropenia - chemically induced | Mitoxantrone - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Prostatic Neoplasms - pathology | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Biomarkers, Tumor - blood | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Pain Measurement | Dosage and administration | Prednisone | Research | Drug therapy | Prostate cancer | Mitoxantrone hydrochloride | Studies | Chemotherapy | Medical imaging | Physicians | Family medical history | Radiation therapy | Clinical medicine | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer
by Liu, Peifeng and Qin, Liubin and Wang, Qi and Sun, Ying and Zhu, Mingjie and Shen, Ming and Duan, Yourong
Biomaterials, ISSN 0142-9612, 2012, Volume 33, Issue 28, pp. 6739 - 6747
Advanced Basic Science | Dentistry | Nanoparticles | Breast cancer | Tumor imaging | Targeted delivery | Tumor therapy | Engineering | Materials Science | Technology | Engineering, Biomedical | Materials Science, Biomaterials | Science & Technology | Mitoxantrone - administration & dosage | Nanoparticles - chemistry | Polylysine - analogs & derivatives | Humans | Polylysine - administration & dosage | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Polylysine - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Peptides, Cyclic - administration & dosage | Peptides, Cyclic - chemistry | Tissue Distribution | Mitoxantrone - chemistry | Polyesters - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - chemistry | Breast Neoplasms - drug therapy | Polyethylene Glycols - administration & dosage | Particle Size | Polyesters - chemistry | Animals | Mice, Nude | Cell Line, Tumor | Breast Neoplasms - diagnosis | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Mitoxantrone - pharmacokinetics | Care and treatment | Biological products | Peptides | Mitoxantrone hydrochloride | Health aspects | Polyols | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma
by Zinzani, Pier Luigi and Gandolfi, Letizia and Broccoli, Alessandro and Argnani, Lisa and Fanti, Stefano and Pellegrini, Cinzia and Stefoni, Vittorio and Derenzini, Enrico and Quirini, Federica and Baccarani, Michele
Cancer, ISSN 0008-543X, 03/2011, Volume 117, Issue 5, pp. 1010 - 1018
chemo‐immunotherapy | midtreatment PET | primary mediastinal large B cell lymphoma | aggressive non‐Hodgkin lymphoma | 18F‐fluorodeoxyglucose positron‐emission tomography | Midtreatment PET | Primary mediastinal large B cell lymphoma | Chemo-immunotherapy | 18F-fluorodeoxyglucose positron-emission tomography | Aggressive non-Hodgkin lymphoma | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Leucovorin - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Lymphoma, Non-Hodgkin - diagnostic imaging | Lymphoma, Non-Hodgkin - pathology | Young Adult | Time Factors | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Drug Administration Schedule | Neoplasm Invasiveness | Rituximab | Etoposide - administration & dosage | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Algorithms | Adolescent | Survival Analysis | Monitoring, Physiologic - methods | Fluorodeoxyglucose F18 | Methotrexate - administration & dosage | Aged | Lymphoma, Non-Hodgkin - mortality | Neoplasm Staging | Care and treatment | Usage | Prognosis | PET imaging | Patient outcomes | Non-Hodgkin's lymphomas | Research | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study
by Burke, Michael J and Kostadinov, Rumen and Sposto, Richard and Gore, Lia and Kelley, Shannon M and Rabik, Cara and Trepel, Jane B and Lee, Min-Jung and Yuno, Akira and Lee, Seonju and Bhojwani, Deepa and Jeha, Sima and Chang, Bill H and Sulis, Maria Luisa and Hermiston, Michelle L and Gaynon, Paul and Van Huynh and Verma, Anupam and Gardner, Rebecca and Heym, Kenneth M and Dennis, Robyn M and Ziegler, David S and Laetsch, Theodore W and Oesterheld, Javier E and Dubois, Steven G and Pollard, Jessica A and Glade-Bender, Julia and Cooper, Todd M and Kaplan, Joel A and Farooqi, Midhat S and Yoo, Byunggil and Guest, Erin and Wayne, Alan S and Brown, Patrick A
Clinical cancer research, ISSN 1078-0432, 05/2020, Volume 26, Issue 10, pp. 2297 - 2307
Life Sciences & Biomedicine | Oncology | Science & Technology | Decitabine - administration & dosage | Prognosis | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Neoplasm Recurrence, Local - pathology | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Female | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Child | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Survival Rate | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Pilot Projects | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vorinostat - administration & dosage | Salvage Therapy - methods | Index Medicus | decitabine | vorinostat | relapse | acute lymphoblastic leukemia | epigenetic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights